Eli Lilly (LLY) EBIAT (2016 - 2025)
Historic EBIAT for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $5.6 billion.
- Eli Lilly's EBIAT rose 47533.75% to $5.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.4 billion, marking a year-over-year increase of 11997.99%. This contributed to the annual value of $10.6 billion for FY2024, which is 10208.38% up from last year.
- As of Q3 2025, Eli Lilly's EBIAT stood at $5.6 billion, which was up 47533.75% from $5.7 billion recorded in Q2 2025.
- In the past 5 years, Eli Lilly's EBIAT ranged from a high of $5.7 billion in Q2 2025 and a low of -$57.4 million during Q3 2023
- Its 5-year average for EBIAT is $2.2 billion, with a median of $1.8 billion in 2023.
- As far as peak fluctuations go, Eli Lilly's EBIAT crashed by 10395.4% in 2023, and later skyrocketed by 179041.81% in 2024.
- Quarter analysis of 5 years shows Eli Lilly's EBIAT stood at $1.7 billion in 2021, then increased by 12.26% to $1.9 billion in 2022, then grew by 13.01% to $2.2 billion in 2023, then surged by 101.39% to $4.4 billion in 2024, then rose by 26.59% to $5.6 billion in 2025.
- Its EBIAT stands at $5.6 billion for Q3 2025, versus $5.7 billion for Q2 2025 and $2.8 billion for Q1 2025.